Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Association of nutritional indices with early clinical remission in patients with moderate-to-severe ulcerative colitis treated with vedolizumab. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s0140-6736(17)32448-0
10.1016/s0140-6736(17)32448-0 · External reference
10.1111/apt.17389
10.1111/apt.17389 · External reference
10.3390/nu16121826
10.3390/nu16121826 · External reference
10.1093/ecco-jcc/jjw092
10.1093/ecco-jcc/jjw092 · External reference
10.1007/s00535-018-1480-0
10.1007/s00535-018-1480-0 · External reference
10.1053/j.gastro.2024.10.001
10.1053/j.gastro.2024.10.001 · External reference
10.1093/ecco-jcc/jjad043
10.1093/ecco-jcc/jjad043 · External reference
10.1016/j.cgh.2020.02.010
10.1016/j.cgh.2020.02.010 · External reference
10.1007/s10238-025-01601-6
10.1007/s10238-025-01601-6 · External reference
10.1177/2050640620965106
10.1177/2050640620965106 · External reference
Predictors of the efficacy of vedolizumab in patients with ulcerative colitis
2024 · External reference
The systemic immune-inflammation index is superior to predicting clinical remission and relapse for ulcerative colitis patients treated with vedolizumab
2025 · External reference
10.3390/pharmaceutics16121629
10.3390/pharmaceutics16121629 · External reference
10.1016/j.cgh.2022.07.027
10.1016/j.cgh.2022.07.027 · External reference
10.3390/nu15010240
10.3390/nu15010240 · External reference
The value of 7 peripheral blood serum ratios in diagnosis and prediction of disease activity of patients within inflammatory bowel disease individuals
2023 · External reference
10.1111/jgh.15161
10.1111/jgh.15161 · External reference
10.1186/s12876-025-04125-1
10.1186/s12876-025-04125-1 · External reference
10.1093/ecco-jcc/jjab178
10.1093/ecco-jcc/jjab178 · External reference
10.7326/0003-4819-147-8-200710160-00010
10.7326/0003-4819-147-8-200710160-00010 · External reference
10.1093/ajcn/87.1.106
10.1093/ajcn/87.1.106 · External reference
10.3389/fnut.2024.1398690
10.3389/fnut.2024.1398690 · External reference
10.1080/07853890.2024.2443256
10.1080/07853890.2024.2443256 · External reference
10.1016/s0140-6736(23)00966-2
10.1016/s0140-6736(23)00966-2 · External reference
10.1080/09637486.2021.1906212
10.1080/09637486.2021.1906212 · External reference
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
2018 · External reference
10.1093/ajcn/82.4.777
10.1093/ajcn/82.4.777 · External reference
10.1016/0002-9610(80)90246-9
10.1016/0002-9610(80)90246-9 · External reference
10.3390/jcm14061937
10.3390/jcm14061937 · External reference
10.1177/0148607114566656
10.1177/0148607114566656 · External reference
10.1093/ibd/izae140
10.1093/ibd/izae140 · External reference
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
2024 · External reference
10.3390/nu18050829
10.3390/nu18050829 · External reference
The predictive value of SII, PNI, AGR on the severity of ulcerative colitis
2024 · External reference
10.1080/03007995.2023.2257599
10.1080/03007995.2023.2257599 · External reference
10.1111/apt.15484
10.1111/apt.15484 · External reference
10.1159/000527846
10.1159/000527846 · External reference
10.1111/j.1751-2980.2008.00350.x
10.1111/j.1751-2980.2008.00350.x · External reference
10.1056/nejmra1804281
10.1056/nejmra1804281 · External reference
10.1093/ibd/izaa062
10.1093/ibd/izaa062 · External reference
10.1111/j.1572-0241.2004.04129.x
10.1111/j.1572-0241.2004.04129.x · External reference
10.1016/j.jcmg.2023.08.019
10.1016/j.jcmg.2023.08.019 · External reference
10.3389/fimmu.2020.595835
10.3389/fimmu.2020.595835 · External reference
10.1371/journal.pone.0059321
10.1371/journal.pone.0059321 · External reference
10.1093/ecco-jcc/jjz042
10.1093/ecco-jcc/jjz042 · External reference
